

| Metric          | CQC Key Question                                                                                                                       | 2017 Report <sup>1</sup> | 2018 Report <sup>2</sup>            | National Aggregate (England & Wales) | National Aspirational Standard | Comparison to other trusts |                                            |   |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------|--------------------------|-------------------------------------|--------------------------------------|--------------------------------|----------------------------|--------------------------------------------|---|
| All patients    | Crude proportion of patients seen by a Cancer Nurse Specialist                                                                         | Responsive               | 13.40%                              | #VALUE!                              | TBC                            | 90%*                       | Meets the national minimum standard of 90% | ▲ |
| 220 cases       | Case mix adjusted one year relative survival rate                                                                                      | Effective                | 40.30%<br>Within the expected range | 44.4%                                | 36.7%                          | None                       | Better than expected                       | ▲ |
| NSCLC 220 cases | Case mix adjusted percentage of patients with Non Small Cell Lung Cancer (NSCLC) receiving surgery                                     | Effective                | 19.7%<br>Within the expected range  | 23.2%                                | 18.4%                          | 17%*                       | Within the expected range                  | ■ |
| NSCLC 220 cases | Case mix adjusted percentage of fit patients with advanced Non Small Cell Lung Cancer (NSCLC) receiving Systemic Anti-Cancer Treatment | Effective                | 83.3%<br>Positive outlier           | 80.2%                                | 65.1%                          | 65%*                       | Within the expected range                  | ■ |
| SCLC 17 cases   | Case mix adjusted percentage of patients with Small Cell Lung Cancer (SCLC) receiving chemotherapy                                     | Effective                | 71.4%<br>Within the expected range  | 67.8%                                | 70.7%                          | 70%*                       | Within the expected range                  | ■ |